 RESEARCH TRIANGLE PARK, N.C., May 23, 2022 GLOBE NEWSWIRE -- Fennec Pharmaceuticals Inc. NASDAQ:FENC; TSX: FRX, a specialty pharmaceutical company focused on the development of PEDMARKTM a unique formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one investor meetings at the conferences. 